Trinity Biotech buys Bartels for $9.3 million:
This article was originally published in Clinica
Trinity Biotech has bought the assets and goodwill of Intracel division Bartels, a manufacturer of cell dependent infectious agent diagnostics, for $9.3 million in stock and cash. The product range includes antigen detection kits for herpes simplex virus, as well as respiratory viruses, including A and B types flu, para-influenza viruses 1, 2 and 3 and respiratory syncitial virus. It also manufactures and sells infectious disease confirmatory reagents. Dublin, Ireland-based Trinity Biotech says the acquisition of Bartels, based in Issaquah, Washington, will strengthen its distribution capabilities in the US.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.